Fagron NV's latest marketcap:
As of 07/05/2025, Fagron NV's market capitalization has reached $1.91 B. According to our data, Fagron NV is the 6361th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.91 B |
| Revenue (ttm) | 1.03 B |
| Net Income (ttm) | 94.85 M |
| Shares Out | 72.92 M |
| EPS (ttm) | 1.3 |
| Forward PE | 16.64 |
| Ex-Dividend Date | 05/19/2025 |
| Earnings Date | 07/31/2025 |
Fagron NV's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | €1.91 B | 34.87% | 6361 |
| 12/31/2024 | €1.22 B | 0.73% | 7593 |
| 12/29/2023 | €1.21 B | 25.41% | 7224 |
| 12/30/2022 | €967.24 M | -10.3% | 8081 |
| 12/31/2021 | €1.08 B | -21.59% | 8283 |
| 12/31/2020 | €1.38 B | -1.3% | 5928 |
| 12/31/2019 | €1.39 B | 36% | 5296 |
| 12/31/2018 | €1.02 B | 25.1% | 5612 |
| 12/29/2017 | €818.92 M | 17.89% | 7204 |
| 12/30/2016 | €694.64 M | 209.7% | 7892 |
Company Profile
About Fagron NV
Fagron NV is a pharmaceutical compounding company dedicated to delivering personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
Business Segments
The company operates through three key segments:
- Essentials
- Brands
- Compounding Services
Key Products & Services
- DiluCap – A line of excipients for compounding capsule formulations.
- Imuno TF Complex – Supports immune response regulation.
- Pigmerise – A natural phytocomplex for hypopigmentation disorders like vitiligo.
- Pentravan – Used to avoid first-pass metabolism and prevent gastrointestinal erosion.
- Nourisil MD – A first-line therapy for scar and keloid prevention and treatment.
- Neogen – A specialized line of hair care products.
- TrichoConcept – Designed for alopecia treatment.
- Fagron Advanced Derma – Provides skincare, compounded treatments, and personalized dermatological care.
- SyrSpend SF – Ensures pharmaceutical stability, dosage consistency, and patient comfort.
- Cleoderm – A topical cream for personalized dermatological treatments.
Education & Development
Fagron NV also supports the professional development of prescribers and pharmacists through its Fagron Academy.
Company Background
Originally founded in 1990 as Arseus NV, the company rebranded to Fagron NV in January 2015. It is headquartered in Nazareth, Belgium.
Frequently Asked Questions
-
What is Fagron NV's (EBR-FAGR) current market cap?As of 07/05/2025, Fagron NV (including the parent company, if applicable) has an estimated market capitalization of $1.91 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Fagron NV (EBR-FAGR) rank globally by market cap?Fagron NV global market capitalization ranking is approximately 6361 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.